Circio invites to first half 2025 report and R&D update webcast on 28 August

• CEO Dr. Erik D Wiklund and CFO Dr. Lubor Gaal will provide a general corporate update and present the first half 2025 financial results
• CTO Dr. Thomas B Hansen will present recent in vivo data demonstrating further enhancements of Circio´s circVec AAV gene therapy technology

Oslo, Norway 21 August 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, invites to a live webcast at 10:00am CEST on Thursday 28 August 2025. In the webcast, Circio management will provide a corporate update, including the first half 2025 financial results, and present recent in vivo data for its circVec platform technology.

The webcast will include an overview of ongoing testing and optimization of circVec generation 3 for AAV gene therapy, including strong performance in new in vivo settings, as well as an outlook on experimental plans and milestones.

The corporate section will cover Circio´s first half 2025 financial results (unaudited) and provide an update on financing and business development activities in the second half of 2025.

Presenters:
CEO Dr. Erik Digman Wiklund
CFO Dr. Lubor Gaal
CTO Dr. Thomas Birkballe Hansen

Time: 10:00 CEST on 28 August 2025

click here to access the Teams webcast
Meeting ID: 352 997 264 281
Passcode: dj23Wc6o

Participate by phone:
[phone]
Phone conference ID: 591397143#

Questions can be submitted in advance by email to Erik D Wiklund: [e-mail] or directly in the live webcast

A recording of the webcast will be made available on the Circio webpage

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: [phone]
Email: [e-mail]

Lubor Gaal, CFO
Phone: [phone]
Email: [e-mail]

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated over 70-fold prolonged RNA half-life and up to 15-fold enhanced protein expression vs. conventional mRNA vector systems in vivo, and has the potential to become a new gold-standard protein expression technology. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.